TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03371368

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Roux-en-Y Gastric Bypass (RYGBP)
Description: This is a standard RYGBP procedure that would be performed clinically and is not research-specific.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sleeve Gastrectomy (SG)
Description: This is a standard SG procedure that would be performed clinically and is not research-specific.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Very Low Calorie Diet (VLCD)
Description: Weight loss with calorie restricted liquid diet. Subjects will be placed on a 800 kcal/day diet with a meal replacement (Optifast) provided by the investigator for 12 weeks. Then, transitioning to a higher calorie diet intake up to a year. Subjects will be closely monitored by study dietitian
Study: NCT01068405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate: 10mg/week administered in one time, the same day each week (every monday for example)during 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo:10mg/week administered in one time, the same day each week (every monday for example)during 12 months
Study: NCT01145820

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Juice plus
Description: Juice Plus (2 capsules bds) for 11 weeks (10 weeks preop and 1 week postop)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Juice plus
Description: Juice Plus (2 capsules bds) for 11 weeks (10 weeks preop and 1 week postop)
Study: NCT00951171

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrauterine Insemination
Description: The intervention arm will undergo temporary (15 minutes) cervical occlusion with the eliptosphere intracervical catheter. This catheter is typically used to perform saline infusion ultrasounds to image the uterine cavity in our practice.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IUI with the standard inseminator
Description: The control arm will undergo insemination with the standard inseminator (TOmcat catheter).
Study: NCT04429646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous left atrial appendage closure-LAMax
Description: Interventional device, LAMax left atrial appendage closure system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous left atrial appendage closure-Watchman
Description: Interventional device, Watchman® LAA Closure Device
Study: NCT00371462

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Use of PDA + support to reduce weight and pain
Description: participants will attend the MOVE! group, record their food, activity, mood, pain, and weight daily via a PDA. Participants will be assigned a coach to help them set physical activity and calorie goals in order to produce a weight loss of .5%-1% per week on average over the course of 6 months. Participants will continue to log using the PDA during the 2nd 6-months for follow-up. They will also be asked to attend assessments at 3, 6, 9, and 12 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVE! level 2 group weight loss counseling
Description: Participants will attend the MOVE! group and will be asked to complete assessments at 3, 6, 9, and 12 months.
Study: NCT02542410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norethindrone acetate
Study: NCT01709396

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: ED-TBI
Description: Patients will receive 18Gy ED-TBI in 8 fractions of 2.25 Gy each, twice/day for 4 days. Following the final fraction of TBI and an allogeneic hematopoietic stem cell graft.
Study: NCT00940654

Intervention type: OTHER
Intervention: Antipyretic therapy
Description: External cooling;Internal cooling;Non steroid anti inflammatory drugs; Acetaminophen; Steroid
Study: NCT00835510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butenafine cream 1% manufactured by Taro
Description: Treatment applied to affected area twice daily for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lotrimin Ultra (butenafine) 1%
Description: Treatment applied to affected area twice daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Butenafine Vehicle manufactured by Taro
Description: Treatment applied to affected area twice daily for 7 days
Study: NCT02895243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: The study will use a generic prehabilitation program which will include the following components: Warm-up, cardiovascular training, strength training, flexibility training, and cool down. Prehabilitation will occur once per week and approximately 1 hour in duration. Participants will take part in prehabilitation until they receive a kidney transplant which by study design is approximately for 3-6 months.
Study: NCT04069533

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP-L102
Description: CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with lentiviral vector carrying the FANCA gene
Study: NCT00103532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Choices - Motivational Enhancement Intervention
Description: Participants who are randomized to the intervention group will participate in four sessions (over approximately 3 months) of Healthy Choices; a motivational enhancement intervention specifically designed to target multiple risk behaviors in HIV+ youth. Participants will receive individualized referrals at the fourth session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Participants will receive standard care plus referrals at three months post-baseline
Study: NCT00861796

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT01196936

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Assessment
Description: Ancillary Studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality of Life Assessment
Description: Ancillary Studies
Study: NCT00520767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Bortezomib 1.3 mg/m2 days 1, 8, 15, 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Melphalan 9 mg/m2/day days 1-4
Study: NCT01014221

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: acupuncture administered in 8 sessions over 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: 2 weeks of prednisolone 20 mg daily followed by 2 weeks of prednisolone 10 mg daily
Study: NCT01758861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02398058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabectedin
Description: trabectedin will be administered in a 24-h continuous i.v. infusion every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: olaparib will be administered in a continuous daily dose every 12 hours
Study: NCT03197103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC)
Description: For more information read Experimental Arm description
Study: NCT02165904

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adult Autologous Mesenchymal Bone Marrow Cell
Description: Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells.
Study: NCT01801553

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal manipulation
Description: -In the intervention group :~True Lumbopelvic manipulation in supine (A) or in lateral side lying (B) for subjects with LBP:~If for example, A is the best position for both patient-practitioner but after a maximum of two trials doesn't produce a pop sound then the practitioner will move to the B position for a maximum of two trials as well.~-In the control group:~Sham spinal manipulation will realize to mimic (i) the same time, (ii) interaction and (iii) action with the manual therapist but without any efficacy in the position B using the upper body of the patient to target the thoraco-lumbar hinge and not the lumbopelvic region and take the time of handling the patient like in a true SM and mimic a high velocity and short ROM action moving fast his body but with a minimal action on the patient's body.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham spinal manipulation
Study: NCT04917263

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemistry, Flow citometry, Trascriptome analysis
Description: we will perform immunohistochemistry, flow cytometry, transcriptomic analysis, mRNA microarray and mutational profiling

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemistry, Flow citometry, Trascriptome analysis
Description: we will perform immunohistochemistry, flow cytometry, transcriptomic analysis, mRNA microarray and mutational profiling
Study: NCT02230722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Study: NCT02916706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin 20mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01798862

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial injury by hysteroscopy or pipelle sampling

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proceed to COH directly
Study: NCT00927524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glulisine
Description: Dose injection of insulin glargine (Lantus®) given subcutaneously in the abdomen 1 hour prior to breakfast and a dose of insulin glulisine (Apidra®) at a dose based upon your (body wt.) carbohydrate intake for each of the three meals (breakfast, lunch and dinner).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Dose based on carbohydrate intake given subcutaneously in the abdomen prior to breakfast and dinner.
Study: NCT00461643

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins
Study: NCT00664105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be given weekly for seven weeks beginning on Day 1 of the study as a 30-minute intravenous infusion during concurrent therapy.~Carboplatin will be given once every three weeks as a 30-minute intravenous infusion immediately following the infusion of docetaxel. Patients will receive two cycles of consolidation treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be given weekly for seven weeks beginning on Day 1 of the study as a 30-minute intravenous infusion during concurrent therapy.~Docetaxel will be given once every three weeks administered as a one-hour IV infusion. Patients will receive two cycles of consolidation treatment (1 cycle = 3 weeks).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiotherapy will be administered daily X 5 day/week for 34 days beginning on Day 1 of the study. Radiotherapy will follow immediately after the infusions of docetaxel and carboplatin.
Study: NCT02267265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TMW-Newborn Intervention video
Description: This is an educational video intervention developed by the Thirty Million Words® Initiative Lab.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Safe Sleep for your Baby (SIDS) educational video
Description: It is an educational video developed by the National Institute of Child Health and Development (NICHD) promoting the prevention of Sudden Infant Death Syndrome.
Study: NCT02594046

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: stem cell component extract
Description: The Allogeneic Human adipose derived stem cell component extract

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stem cell component extract
Description: The Allogeneic Human adipose derived stem cell component extract
Study: NCT00520767

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Description: ≤28 days prior to enrollment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Day 1 of cycles 6, 12, 18 and at end of study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: ≤28 days prior to enrollment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Start of each cycle
Study: NCT02942043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Group A (low dose group) Intrapleural injection of bevacizumab 2.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.~Group B (medium dose group) Intrapleural injection of bevacizumab 5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.~Group C (high dose group) Intrapleural injection of bevacizumab 7.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Group A (low dose group) Intrapleural injection of bevacizumab 2.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.~Group B (medium dose group) Intrapleural injection of bevacizumab 5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.~Group C (high dose group) Intrapleural injection of bevacizumab 7.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Group A (low dose group) Intrapleural injection of bevacizumab 2.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.~Group B (medium dose group) Intrapleural injection of bevacizumab 5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.~Group C (high dose group) Intrapleural injection of bevacizumab 7.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.
Study: NCT03998137

Intervention type: DEVICE
Intervention: AUGMENT® Injectable Bone Graft
Description: AUGMENT® Injectable Bone Graft

Intervention type: PROCEDURE
Intervention: Standard of Care
Description: Autologous Bone Graft
Study: NCT05380128

Intervention type: GENETIC
Intervention: Genotype analysis for VDR rs1544410, rs2228570, rs731236, and rs7975232 polymorphisms
Description: Genomic DNA was extracted from peripheral blood samples using a Wizard Genomic DNA Purification Kit (Promega, Madison,Wisconsin, USA) as per the product instruction. VDR (rs731236, rs1544410, rs7975232, rs2228570) polymorphisms were genotyped by the improved Multiple Ligase Detection Reaction (iMLDR) developed by Genesky Biotechnologies Inc. (Shanghai, China).

Intervention type: GENETIC
Intervention: Genotype analysis for VDR rs1544410, rs2228570, rs731236, and rs7975232 polymorphisms
Description: Genomic DNA was extracted from peripheral blood samples using a Wizard Genomic DNA Purification Kit (Promega, Madison,Wisconsin, USA) as per the product instruction. VDR (rs731236, rs1544410, rs7975232, rs2228570) polymorphisms were genotyped by the improved Multiple Ligase Detection Reaction (iMLDR) developed by Genesky Biotechnologies Inc. (Shanghai, China).
Study: NCT02491710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training on low-cost box trainer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Training on standard box trainer
Study: NCT03458728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (BAY806946)
Description: Copanlisib will be dosed on Day 1, Day 8, and Day 15 of every 28-day cycle. Phase 1: 2 or 3 dose cohorts may be evaluated in phase 1 of the study. Phase 2: RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (BAY806946)
Description: Copanlisib will be dosed on Day 1, Day 8, and Day 15 of every 28-day cycle. Phase 1: 2 or 3 dose cohorts may be evaluated in phase 1 of the study. Phase 2: RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (BAY806946)
Description: Copanlisib will be dosed on Day 1, Day 8, and Day 15 of every 28-day cycle. Phase 1: 2 or 3 dose cohorts may be evaluated in phase 1 of the study. Phase 2: RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (BAY806946)
Description: Copanlisib will be dosed on Day 1, Day 8, and Day 15 of every 28-day cycle. Phase 1: 2 or 3 dose cohorts may be evaluated in phase 1 of the study. Phase 2: RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (BAY806946)
Description: Copanlisib will be dosed on Day 1, Day 8, and Day 15 of every 28-day cycle. Phase 1: 2 or 3 dose cohorts may be evaluated in phase 1 of the study. Phase 2: RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
Study: NCT03756168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1060nm Diode laser
Description: All subjects received a single treatment with Venus Bliss' 1064 nm laser administered to the flanks~Venus Bliss is a non-invasive medical aesthetic device designed for body contouring. The device contains four 1060 nm diode laser applicators which are 60x60 mm in size. It has a separate RF/PEMF applicator, but this was not used in this study. There is a belt included with the system to allow for the secure attachment of the applicators to the treatment area.
Study: NCT04333732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR or M-M-R II ® vaccine
Description: Education and surveillance plus MR or M-M-R II ® vaccine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection
Study: NCT04587986

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-899
Description: Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BTL-899
Description: Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.
Study: NCT01755910

Intervention type: OTHER
Intervention: Left thoracic paravertebral block

Intervention type: OTHER
Intervention: Right thoracic paravertebral block
Study: NCT00381797

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo fludeoxyglucose F18 PET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study: NCT01937195

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuCath Intravenous Catheter System
Description: AccuCath IV Catheter System will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal. Results will be compared to published literature for conventional IV catheters.
Study: NCT04257422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intentional Rounding
Description: A new method of nursing care named Intentional Rounding. The intentional roundings are planned rounds, conducted at regular intervals by nursing staff to anticipate care, comfort, hospitality and psychological needs of hospitalized users.